Compare American Express Co (AXP) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs Cassava Sciences Inc — how do they compare? American Express Co trades at $341.35 (market cap $230.15B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: American Express Co is far larger — about 4819.9× Cassava Sciences Inc's market cap, and American Express Co pays a 1.11% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AXP | FLNA | |
|---|---|---|
Market Cap | $230.15B | $47.75M |
Sector | Financials | Health |
52-Week High | $384.82 | $4.64 |
52-Week Low | $292.27 | $0.87 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $338.86, down 0.6% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($4.53 vs $4.41 expected) and maintains robust profitability with 15.07% net margin and 33.97% ROE. Recent news highlights Amex Ventures' AI investments and premium card member experiences, while Berkshire Hathaway's 20% ownership underscores long-term confidence in the business model.
AXP presents a mixed outlook with strong fundamental performance offset by technical weakness. The stock offers 9% upside to consensus price target of $369.42, supported by revenue growth and premium positioning, but faces headwinds from bearish technical indicators and competitive pressure in digital payments. Risk-reward appears balanced near current levels.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
